Acadia Shares Double On Phase II Schizophrenia Treatment Success

Acadia Pharmaceuticals shareholders got a strong dose of good news yesterday, when the company announced its ACP-103 schizophrenia treatment showed effectiveness in its Phase II trials. Shares shot up $6.92, or 103.44%, to $13.61 on the news. The company reported that when combined with other antipsychotic treatments, the trial showed a statistically significant level of efficacy as well as reduced negative side effects, including "a faster onset of antipsychotic action and 50% less weight gain,” according to Uli Hacksell, Acadia's CEO. According to Caancord analyst Jose Pantginis, "Acadia is such a small company, that even if it gets a sliver of that $13 to $14 billion [antipsychotic meds] pie, the impact to its bottom line would be huge."

We only use your contact details to reply to your request for more information.We do not sell the personal contact data you submit to anyone else.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you shortly for a conversation.

Thank you for your interest in Seeking Alpha PRO

Our PRO subscription service was created for fund managers, and the cost of the product is
prohibitive for most individual investors.
If you are an investment professional with over $1M AUM and received this message
in error, click here and you will be contacted shortly.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you when we have an individual investor product ready!